Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Letter Commentary & Co-Mentions | Period / Date | Action |
|---|---|---|---|
“RTW Biotech Opportunities delivered -6.4% NAV return in Q1 2025, outperforming the Russell 2000 Biotech Index (-13.6%) amid a challenging environment marked by Trump's trade war initiation and biotech sector sell-off. The fund maintains...” | Q1 2025 Mar 31, 2025 | Preview | |
“RTW Biotech Opportunities delivered a -7.3% quarterly return and -4.6% for 2024, while celebrating its fifth anniversary with an 86.3% five-year NAV return that outperformed biotech indices. The fund maintains...” | Q4 2024 Dec 31, 2024 | Preview |
Read unredacted commentary excerpts, portfolio weight disclosures, and high-conviction theses from hedge fund managers discussing $IMCR.
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
